Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Rating) EVP Craig E. Hunsaker sold 9,895 shares of the business’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $9.07, for a total value of $89,747.65. Following the transaction, the executive vice president now directly owns 1,251,174 shares of the company’s stock, valued at approximately $11,348,148.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Alphatec Trading Down 5.4 %
Shares of Alphatec stock traded down $0.51 on Wednesday, hitting $8.93. The stock had a trading volume of 475,949 shares, compared to its average volume of 699,550. The stock has a 50 day moving average of $7.34 and a 200 day moving average of $9.26. Alphatec Holdings, Inc. has a twelve month low of $5.73 and a twelve month high of $15.31. The company has a debt-to-equity ratio of 29.74, a quick ratio of 1.34 and a current ratio of 2.19. The firm has a market capitalization of $934.58 million, a P/E ratio of -5.51 and a beta of 1.62.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new stake in Alphatec in the fourth quarter valued at approximately $356,000. Advisor Group Holdings Inc. boosted its holdings in Alphatec by 65.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 35,787 shares of the medical technology company’s stock valued at $408,000 after acquiring an additional 14,153 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Alphatec by 1,344.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 374,788 shares of the medical technology company’s stock valued at $4,284,000 after acquiring an additional 348,834 shares during the last quarter. Cullen Frost Bankers Inc. boosted its holdings in Alphatec by 4.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 55,365 shares of the medical technology company’s stock valued at $633,000 after acquiring an additional 2,385 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Alphatec in the fourth quarter valued at approximately $177,000. Institutional investors and hedge funds own 53.52% of the company’s stock.
Analysts Set New Price Targets
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.
- Get a free copy of the StockNews.com research report on Alphatec (ATEC)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe’s Stands Out Amid Q2 Retail Reports
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.